EUVIMEDEUVIMED entdecken
Crossref

Prostaglandin-Associated Periorbitopathy Symptom Alleviation After Switching Prostaglandin F Receptor Agonist to EP2 Receptor Agonist in Patients with Glaucoma

Rei Sakata iD, Takashi Fujishiro, Hitomi Saito, Natsuko Nakamura, Megumi Honjo, Shiroaki Shirato, Etsuyo Miyamoto, Yoshiaki Yamada, Makoto Aihara

Journal of Ocular Pharmacology and Therapeutics · 01.02.2023 · 39 (1) · 63-69

DOI: 10.1089/jop.2022.0096 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Ocular Pharmacology and Therapeutics, online erschienen am 25.01.2023. Verfasst von Rei Sakata und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Ophthalmology, Graduate of Medicine and Faculty of Medicine, The University of Tokyo, Tokyo, Japan. Hauptthemen laut MEDLINE: Eyelid Diseases, Orbital Diseases, Glaucoma, Prostaglandins F, Synthetic. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 28 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

Prostaglandin-associated periorbitopathy in patients with glaucoma is reportedly not caused by EP2 agonist, but it has been a cosmetic problem with prostaglandin F receptor (FP) agonists. In this study, patients with prostaglandin-associated periorbitopathy on FP agonists were switched to EP2 agonist and changes were investigated.

Methods

Patients complaining of prostaglandin-associated periorbitopathy were included. The FP agonist was switched to EP2 agonist (omidenepag isopropyl), and patients were followed up for 7 months. Frontal photographs were taken at every visit, and objective changes in deepening of the upper eyelid sulcus were assessed by three observers. Subjective questionnaires (self-awareness of deepening of the upper eyelid sulcus, eyelid/peri-eyelid skin pigmentation, eyelash elongation, and conjunctival hyperemia) were acquired at the start and the endpoint. Factors associated with the change of prostaglandin-associated periorbitopathy were investigated using logistic regression analysis.

Results

Included were 23 eyes of 23 patients (17 women; 60.6 years). At 7 months, objective deepening of the upper eyelid sulcus improved by 76%. The subjective questionnaires showed that deepening of the upper eyelid sulcus improved in 95%, eyelid/peri-eyelid skin pigmentation in 76%. The less extent of myopia was a significant factor in the eyes with improved eyelid/peri-eyelid skin pigmentation. After switching, no change in intraocular pressure or visual acuity was observed ( P ≥ 0.22).

Conclusion

Switching to omidenepag isopropyl increased patient satisfaction and might be the first step to lightening deepening of the upper eyelid sulcus and eyelid/peri-eyelid skin pigmentation. It was suggested that pigmentation may be more easily improved in nonmyopic eyes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Eyelid DiseasesOrbital DiseasesGlaucomaProstaglandins F, SyntheticHumansFemaleAntihypertensive AgentsIntraocular Pressure

Stichwörter der Autor:innen

EP2 receptor agonistFP receptor agonistseyelid/peri-eyelid skin pigmentationglaucomaomidenepag isoprorylupper eyelid sulcus

Substanzen

Antihypertensive AgentsProstaglandins F, Synthetic

Autor:innen und Institutionen

  • Department of Ophthalmology, Graduate of Medicine and Faculty of Medicine, The University of Tokyo, Tokyo, Japan.
  • Yotsuya Shirato Eye Clinic, Tokyo, Japan.
  • Santen Pharmaceutical Co., Ltd., Osaka, Japan.

ORCID-Profile: Rei Sakata

Zitieren

APA

Sakata, R., Fujishiro, T., Saito, H., Nakamura, N., Honjo, M., Shirato, S., Miyamoto, E., Yamada, Y., & Aihara, M. (2023). Prostaglandin-Associated Periorbitopathy Symptom Alleviation After Switching Prostaglandin F Receptor Agonist to EP2 Receptor Agonist in Patients with Glaucoma. Journal of Ocular Pharmacology and Therapeutics, 39(1), 63-69. https://doi.org/10.1089/jop.2022.0096

Vancouver

Sakata R, Fujishiro T, Saito H, Nakamura N, Honjo M, Shirato S, et al. Prostaglandin-Associated Periorbitopathy Symptom Alleviation After Switching Prostaglandin F Receptor Agonist to EP2 Receptor Agonist in Patients with Glaucoma. Journal of Ocular Pharmacology and Therapeutics. 2023;39(1):63-69. doi:10.1089/jop.2022.0096

BibTeX
@article{Sakata2023,
  author = {Sakata, Rei and Fujishiro, Takashi and Saito, Hitomi and Nakamura, Natsuko and Honjo, Megumi and Shirato, Shiroaki and Miyamoto, Etsuyo and Yamada, Yoshiaki and Aihara, Makoto},
  title = {Prostaglandin-Associated Periorbitopathy Symptom Alleviation After Switching Prostaglandin F Receptor Agonist to EP2 Receptor Agonist in Patients with Glaucoma},
  journal = {Journal of Ocular Pharmacology and Therapeutics},
  year = {2023},
  volume = {39},
  number = {1},
  pages = {63--69},
  doi = {10.1089/jop.2022.0096}
}
Kostenlos starten →